Xiaoping Su

The University of Texas MD Anderson Cancer Center

Full Professor(heuristic)

Renal cell carcinoma treatment · Pulmonary and Respiratory Medicine

h-index80

i10-index172

Publications732

Citations45,071

Grants

11 total · 0 active

NIH #5U01CA172027-05

Quantitative MRSI to predict early response to SAHA therapy in new GBM management

Amount: $617K
Period: 2013-08-06 → 2018-10-31
PIs: 5
Est. capacity / PI: ~0 students

Awarded at EMORY UNIVERSITY

NIH #4U01CA172027-04

Quantitative MRSI to predict early response to SAHA therapy in new GBM management

Amount: $624K
Period: 2013-08-06 → 2018-07-31
PIs: 5
Est. capacity / PI: ~0 students

Awarded at EMORY UNIVERSITY

NIH #5U01CA172027-02

Quantitative MRSI to predict early response to SAHA therapy in new GBM management

Amount: $627K
Period: 2013-08-06 → 2018-07-31
PIs: 5
Est. capacity / PI: ~0 students

Awarded at EMORY UNIVERSITY

Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.

All Grants

11 total · 0 active

NIH #5U01CA172027-05

Quantitative MRSI to predict early response to SAHA therapy in new GBM management

Amount: $617K
Period: 2013-08-06 → 2018-10-31
PIs: 5
Est. capacity / PI: ~0 students

Awarded at EMORY UNIVERSITY

NIH #4U01CA172027-04

Quantitative MRSI to predict early response to SAHA therapy in new GBM management

Amount: $624K
Period: 2013-08-06 → 2018-07-31
PIs: 5
Est. capacity / PI: ~0 students

Awarded at EMORY UNIVERSITY

NIH #5U01CA172027-02

Quantitative MRSI to predict early response to SAHA therapy in new GBM management

Amount: $627K
Period: 2013-08-06 → 2018-07-31
PIs: 5
Est. capacity / PI: ~0 students

Awarded at EMORY UNIVERSITY

NIH #1U01CA172027-01

Quantitative MRSI to predict early response to SAHA therapy in new GBM management

Amount: $671K
Period: 2013-08-06 → 2018-07-31
PIs: 5
Est. capacity / PI: ~0 students

Awarded at EMORY UNIVERSITY

NIH #5R21AI103652-02

Study Sox4 regulated genes in B cell development in a novel in vitro system

Amount: $200K
Period: 2014-08-01 → 2017-07-31
PIs: 1
Est. capacity / PI: ~0 students

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

NIH #5U01CA172027-03

Quantitative MRSI to predict early response to SAHA therapy in new GBM management

Amount: $633K
Period: 2013-08-06 → 2016-07-31
PIs: 5
Est. capacity / PI: ~0 students

Awarded at EMORY UNIVERSITY

NIH #1R21AI103652-01A1

Study Sox4 regulated genes in B cell development in a novel in vitro system

Amount: $240K
Period: 2014-08-01 → 2016-07-31
PIs: 1
Est. capacity / PI: ~0 students

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

NIH #5R21CA141836-02

Using Proton MRS to Predict Response of SAHA treatment in Glioblastoma

Amount: $327K
Period: 2010-04-01 → 2013-03-31
PIs: 3
Est. capacity / PI: ~0 students

Awarded at EMORY UNIVERSITY

NIH #5R03AI079779-02

Role of Sox4 in B Cell Development

Amount: $78K
Period: 2010-07-01 → 2012-06-30
PIs: 1
Est. capacity / PI: ~0 students

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

NIH #1R03AI079779-01A1

Role of Sox4 in B Cell Development

Amount: $79K
Period: 2010-07-01 → 2012-06-30
PIs: 1
Est. capacity / PI: ~0 students

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

NIH #1R21CA141836-01A2

Using Proton MRS to Predict Response of SAHA treatment in Glioblastoma

Amount: $337K
Period: 2010-04-01 → 2012-03-31
PIs: 3
Est. capacity / PI: ~0 students

Awarded at EMORY UNIVERSITY

Lab Funding Health

Find elsewhere

Institution / lab homepage Search on ResearchGate

In-Field Influence

0.0021

PageRank within Pulmonary and Respiratory Medicine co-authorship network

Explore collaboration map

Admission Signals

New paper: Pancreatitis Risk Genes Play a Major Role in Pediatric Pancreatitis: Insights From INSPPIRE (Clinical Gastroenterology and Hepatology)2026-06-01

Data Freshness

Publications as of 2026-07-01
Grants as of 2026-06-30

Are you this professor?

No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.

ORCID: 0000-0003-1824-943X

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 138

Pancreatitis Risk Genes Play a Major Role in Pediatric Pancreatitis: Insights From INSPPIRE
Clinical Gastroenterology and Hepatology · 2026-06-01
945 EXPANDED GENETIC TESTING IN PATIENTS WITH RECURRENT ACUTE AND CHRONIC PANCREATITIS REVEALS NEW VARIANTS LINKED TO THE DISEASE
Gastroenterology · 2026-05-01
945 EXPANDED GENETIC TESTING IN PATIENTS WITH RECURRENT ACUTE AND CHRONIC PANCREATITIS REVEALS NEW VARIANTS LINKED TO THE DISEASE
Gastrointestinal Endoscopy · 2026-05-01
Long non-coding RNA (lncRNA) CDKN2A-DT promotes proliferation, migration, and invasion of oral squamous cell carcinoma via the PI3K/AKT/mTOR axis
Translational Cancer Research · 2026-04-01
BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML
Leukemia · 2025-12-19 · 2 citations
Stromal fibroblastic mutant Trp53 promotes mammary tumor development via enhanced secretion of paracrine factors
npj Breast Cancer · 2025-12-12
Supplementary Tables S1-S9 and Figures S1-S9 from Dimeric p53 Mutant Elicits Unique Tumor-Suppressive Activities through an Altered Metabolic Program
2025-12-11
Abstract B002: Addressing knowledge gaps in early-onset cancers: Radiological insights into oncogenic-immune dynamics of anaplastic Wilms tumors
Clinical Cancer Research · 2025-12-10
Figure S5 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025-11-25
Figure S3 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025-11-25
Figure S8 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025-11-25
Figure S7 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025-11-25
Figure S2 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025-11-25
Figure S4 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025-11-25
Figure S1 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025-11-25
Supplementary Tables TS1-23 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025-11-25
Figure S6 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
2025-11-25
Supplementary Table 5 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
2025-11-24
Supplementary Figure Annotations from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
2025-11-24
Supplementary Figures from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
2025-11-24

Open author page on OpenAlex →